Hovione Technology acquires rights to pulmonary inhaler

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Magicmine)
(Image: Getty/Magicmine)

Related tags: Copd, Asthma, Inhaler, Hovione Technology

Hovione Technology reaches an agreement to acquire the global rights to a reusable, cost-efficient, dry-powder inhaler.

Prior to CPhI North America, Hovione Technology stated that it will license a dry powder inhaler (DPI) design from its inventor, Klaus-Dieter Beller, and his own privately run company, Med & Tec.

The one part system is able to load and automatically pierce a single or double blister, with doses of up to 50mg supported.

According to Hovione Technology, the reusable device, to be called Papillon, is an ‘ultra-affordable’, could reduce the complexity of pulmonary devices due to it being comprised of a single part.

Hovione Technology - Papillon DPI (1)
Papillion inhaler. Image: Hovione Technology

The device can be used for chronic or acute pulmonary conditions, with Hovione Technology providing examples of potential uses in asthma or chronic obstructive pulmonary disease. It also has potential uses in the delivery of cystic fibrosis treatments, antibiotics, and anti-viral drugs.

Hovione Technology’s CEO, Peter Villax, said: “This is a strategic DPI development for Hovione Technology which emphasises our long-term commitment to offer market access to a portfolio of innovative inhalers that maximize simplicity of use, drug delivery performance and cost-effectiveness on a truly global scale. We are delighted to accelerate commercialisation of this innovative blister DPI”.

Hovione Technology will continue to develop the device in collaboration with its inventor, Beller, and is already available for licensing and supply.

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us

Products

View more

Webinars